Translational Functional Neuroimaging in the Explanation of Depression

Year 2017, Volume: 34 Issue: 6, 493 - 503, 01.11.2017

Drozdstoy Stoyanov Sevdalina Kandilarova Stefan Borgwardt

Abstract

Translation as a notion and procedure is deeply embodied in medical science and education. Translation includes the possibility to translate data across disciplines to improve diagnosis and treatment procedures. The evidence accumulated using translation serves as a vehicle for reification of medical diagnoses. There are promising, established post hoc correlations between the different types of clinical tools (interviews and inventories) and neuroscience. The various measures represent statistical correlations that must now be integrated into diagnostic standards and procedures but this, as a whole, is a step forward towards a better understanding of the mechanisms underlying psychopathology in general and depression in particular. Here, we focus on functional magnetic resonance imaging studies using a trans-disciplinary approach and attempt to establish bridges between the different fields. We will selectively highlight research areas such as imaging genetics, imaging immunology and multimodal imaging, as related to the diagnosis and management of depression.

Keywords

Neuroscience, translational medical research, depression, neuroimaging, functional

References

• 1. WHO, Global burden of mental disorders and the need for a comprehensive, coordinated response from health and social sectors at the country level. WHO: Geneva; 2011.
• 2. Rush AJ, Trivedi M, Carmody TJ, Biggs MM, Shores-Wilson K, Ibrahim H, et al. One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol Psychiatry 2004;56:46-53.
• 3. Markova IS. Reification in psychiatry, in Traditions and Innovations in Psychiatry, WPA Regional Meeting Materials. St. Petersburg; 2010:48-9.
• 4. Stoyanov DS, Machamer PK, Schaffner KF, In Quest for Scientific Psychiatry: towards bridging the explanatory gap. Philosophy, Psychiatry, Psychology 2013;20:261-73.
• 5. Borgwardt S, Radua J, Mechelli A, Poli PF. Why are psychiatric imaging methods clinically unreliable? Conclusions and practical guidelines for authors, editors and reviewers. Behav Brain Funct 2012.
• 6. Stojanov D, Korf J, Jonge P. The possibility of evidence-based psychiatry: depression as a case. Clin Epigenetics 2011;2:7-15.
• 7. Hariri AR, Weinberger DR. Imaging genomics. Br Med Bull 2003;65:259- 70.
• 8. López-León S, Janssens AC, González-Zuloeta Ladd AM, Del-Favero J, Claes SJ, Oostra BA, et al. Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry 2008;13:772-85.
• 9. YosifovaA, Mushiroda T, Stoianov D, Vazharova R, Dimova I, Karachanak S, et al. Case-control association study of 65 candidate genes revealed a possible association of a SNP of HTR5A to be a factor susceptible to bipolar disease in Bulgarian population. J Affect Disord 2009;117: 87-97.
• 10. Gatt JM, Burton KL, Williams LM, Schofield PR. Specific and common genes implicated across major mental disorders: A review of meta-analysis studies. J Psychiatr Res 2015;60:1-13.
• 11. Wurtman RJ. Genes, stress, and depression. Metabolism 2005;54(5 Suppl 1):16-9.
• 12. Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, Egan MF, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002;297:400-3.
• 13. Heinz A, Braus DF, Smolka MN, Wrase J, Puls I, Hermann D, et al. Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat Neurosci 2005;8:20-1.
• 14. Pezawas L, Meyer-LindenbergA, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, et al. 5-HTTLPR polymorphism impacts human cingulateamygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 2005;8:828-34.
• 15. Pizzagalli DA. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 2011;36:183-206.
• 16. Clarke H, Flint J, Attwood AS, Munafò MR. Association of the 5- HTTLPR genotype and unipolar depression: a meta-analysis. Psychol Med 2010;40:1767-78.
• 17. Brockmann H, Zobel A, Schuhmacher A, Daamen M, Joe A, Biermann K, et al. Influence of 5-HTTLPR polymorphism on resting state perfusion in patients with major depression. J Psychiatr Res 2011;45:442-51.
• 18. Costafreda SG, McCann P, Saker P, Cole JH, Cohen-Woods S, Farmer AE, et al. Modulation of amygdala response and connectivity in depression by serotonin transporter polymorphism and diagnosis. J Affect Disord 2013;150:96-103.
• 19. Dannlowski U, Ohrmann P, Bauer J, Kugel H, Baune BT, Hohoff C, et al. Serotonergic genes modulate amygdala activity in major depression. Genes Brain Behav 2007;6:672-6.
• 20. Friedel E, Schlagenhauf F, Sterzer P, Park SQ, Bermpohl F, Ströhle A, et al. 5-HTT genotype effect on prefrontal-amygdala coupling differs between major depression and controls. Psychopharmacology (Berl) 2009;205:261- 71.
• 21. Margoob MA, Mushtaq D, Murtza I, Mushtaq H, Ali A. Serotonin transporter gene polymorphism and treatment response to serotonin reuptake inhibitor (escitalopram) in depression: An open pilot study. Indian J Psychiatry 2008;50:47-50.
• 22. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000;23:587-90.
• 23. Ng CH, Easteal S, Tan S, Schweitzer I, Ho BK, Aziz S. Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:953-7.
• 24. Kraft JB, Peters EJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ, et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 2007;61:734-42.
• 25. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012;22:239-58.
• 26. GENDEP Investigators; MARS Investigators; STAR*D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry 2013;170:207-17.